Company profile for Elysium Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Elysium is a rising biopharmaceutical firm pioneering enhanced safety standards in the opioid sector through the development of SMART™ (Safer Medicines Alleviate Risks and Trauma) products. These innovative medications aim to mitigate the limitations and hazards linked with opioids and overdose rescue agents, thereby alleviating suffering from opioid-use disorder, opioid overdose, and acute pain. The company's flagship SMART...
Elysium is a rising biopharmaceutical firm pioneering enhanced safety standards in the opioid sector through the development of SMART™ (Safer Medicines Alleviate Risks and Trauma) products. These innovative medications aim to mitigate the limitations and hazards linked with opioids and overdose rescue agents, thereby alleviating suffering from opioid-use disorder, opioid overdose, and acute pain. The company's flagship SMART opioid product candidate, oral-overdose protected (O2P™) hydrocodone, is undergoing development for the management of moderate-to-severe acute pain.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1201 East Market Street, Suite 604, Akron, OH 44305, United States
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/elysium-therapeutics-completes-pre-ind-meeting-with-fda-for-first-ever-technology-designed-to-combat-oral-fentanyl-overdose-302533882.html

PR NEWSWIRE
20 Aug 2025

https://www.prnewswire.com/news-releases/elysium-therapeutics-investor-webcast-highlights-fentanyl-rebound-as-key-challenge-in-reducing-opioid-overdose-hospitalizations-and-deaths-302479378.html

PR NEWSWIRE
11 Jun 2025

https://www.prnewswire.com/news-releases/elysium-therapeutics-to-participate-in-the-2025-bio-international-convention-to-discuss-challenge-of-fentanyl-rebound-and-rescue-medication-designed-for-synthetic-opioids-302473757.html

PR NEWSWIRE
05 Jun 2025

https://www.prnewswire.com/news-releases/elysium-therapeutics-to-host-investor-webcast-highlighting-soopr-program-and-the-need-to-address-fentanyl-rebound-as-key-challenge-in-the-opioid-overdose-epidemic-302452576.html

PR NEWSWIRE
12 May 2025

https://www.prnewswire.com/news-releases/elysium-therapeutics-announces-development-of-overdose-rescue-technology-specifically-designed-for-oral-fentanyl-302421250.html

PR NEWSWIRE
07 Apr 2025

https://www.prnewswire.com/news-releases/elysium-therapeutics-presents-phase-1-proof-of-concept-results-for-novel-smart-o2p-opioid-technology-for-acute-pain-that-reduces-the-potential-for-abuse-diversion-and-risk-of-oral-overdose-at-painweek-2024-302235155.html

PR NEWSWIRE
03 Sep 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty